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A series of 28 adenosine analogs and 17 xanthines has been assessed as inhibitors of binding of N6-Rj3H]- 
phenylisopropyladenosine bi ding to Al adenosine r ceptors in membranes from rat, calf, and guinea pig 
brain. Potencies of N6-alkyl- and @cycloalkyladenosines are similar in the different species. However, the 
presence ofan aryl or heteroaryl moiety in the N6 substituent results in marked species differences with cer- 
tain such analogs being about 30-fold more potent at receptors in calf than in guinea pig brain. Potencies 
at receptors in rat brain are intermediate. Conversely, 2-chloroadenosine and 5’-N-ethylcarboxamido- 
adenosine are about lo-fold less potent at receptors in calf brain than in guinea pig brain. Potencies of 
xanthines, such as theophylline, caffeine and 1,3_dipropylxanthine are similar in the different species. How- 
ever, the presence of an 8-phenyl or 8-cycloalkyl substituent results in marked species differences. For exam- 
ple, a xanthine amine conjugate of 1,3-dipropyl-8-phenylxanthine is g-fold more potent at receptors in calf 
than in rat brain and 1 IO-fold more potent in calf than in guinea pig brain. Such differences indicate that 
brain Al adenosine receptors are not identical in recognition sites for either agonists or antagonists in differ- 
ent mammalian species. 
Adenosine agonist Xanthine antagonist Aaknosine receptor Structure-activity 
1. INTRODUCTION 
A wide range of studies have provided evidence 
for two classes of adenosine receptors, one in- 
hibitory (Al) and the other stimulatory (A2) to 
adenylate cyclase (reviews [1,2]). In addition to 
having opposite effects on the adenylate cyclase ac- 
tivity, the two types of receptor differ according to 
the potency order within a limited set of adenosine 
analogs. However, ambiguity has arisen when 
these analogs were used to identify the type of 
receptor involved in physiological responses, either 
in vivo or in isolated tissues. This led to the sugges- 
tion that there is but one type of adenosine recep- 
tor [3]. One reason for ambiguous results may be 
species differences in adenosine receptors. Initial 
studies [4,5] showed differences in the potency of 
various ligands at binding sites in rat, calf and 
guinea pig brains: the binding properties of 
tritiated adenosine analogs were similar in brain of 
different species, while the antagonist 1,3-di- 
ethyl-S-phenylxanthine showed considerable dif- 
ferences in affinity for brain Al receptors. Recent 
studies indicate that the [3H]xanthine amine con- 
gener of the antagonist 1,3_dipropylxanthine also 
shows marked species differences in affinity for 
brain Al receptors [6]. 
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2. MATERIALS AND METHODS materials were from standard sources [6]. 
Synthetic procedures have been described for the 
Membranes from rat, calf and guinea pig various adenosine analogs and xanthines or were 
cerebral cortex were prepared as described [6]. The by standard methods (see [7-121). 
binding of 1 nM 3H-labeled N6-R-1-phenyl-2- 
propyladenosine ([3H]PIA) to these membranes at 
37°C was assayed essentially as in [6]. I& values 3. RESULTS 
were transformed into Ki WdUeS using a & for 
[3H]PIA binding of 1 .O nM in rat, 0.52 nM in calf N6-Alkyl- and N6-cycloalkyladenosine analogs 
and 4.9 nM in guinea pig brain [6]. Chemicals and (compounds 1-8) show nearly the same affinity at 
Table 1 
Inhibition of [3H]PIA binding to cerebral cortex membranes by adenosine analogs 
Adenosine analog Inhibition [3H]PIA binding (Ki, nM) 
Rat Calf Guinea pig 
1 N6- 1-Butyl- 
2 N6-Cyclobutyl- 
3 N6-3-Pentyl- 
4 I@-2-Methyl-2-propyl- 
5 N6-Cyclopentyl- 
6 N6-l-Methylcyclopentyl- 
7 I@-Cyclohexyl- 
8 I@-Cyclooctyl- 
9 I@-Phenyl- 
10 N6-Benzyl- 
11 N6-2-Phenethyl- 
12 N6-2-(3-Pyridylethyl)- 
13 N6-2-(4-Pyridylethyl)- 
14 N6-2-(2-Thienylethyl)- 
15 N6-CHsNHCOCH&&- 
16 N6-CHsC&NHCOCH2C&- 
17 N~-H~N(CH~)ZNHCOCH&~H~- 
NHCOCH&H4- (ADAC) 
18 N6-R-l-Phenyl-Zpropyl- (R-PIA) 
19 N6-S-1-Phenyl-2-propyl- (S-PIA) 
20 N6-2-Methyl-2-propyl- (MePIA) 
21 5 ’ -N-Ethylcarboxamido- (NECA) 
22 5 ’ -N-Methylcarboxamido 
23 5 ’ -Carboxamido- 
24 2-Chloro- 
25 2-Phenylamino- 
26 N6-Cyclohexyl-NECA 
27 I@-R-I-Phenyl-2-propyl-NECA 
28 I@-& 1-Phenyl-2-propyl-NECA 
6.3 (4.4-9.1) 
0.84 (0.59-1.2) 
1 .O (0.69-l 5) 
20.4 (12.2-34) 
0.34 (0.27-0.41) 
1.4 (1.0-1.9) 
1 .O (0.69-l .6) 
5.4 (4.2-6.8) 
16.4 (9.7-28) 
175 (120-260) 
16.1 (12.3-21.0) 
10.4 (7.3-14.9) 
16.2 (8.9-29.4) 
6.8 (2.5-17.5) 
13.2 (7.9-21.8) 
1.7 (0.77-3.9) 
1.3 (1.0-1.7) 
1.2 (0.89-1.5) 
1::: ~zz#O) 
7.8 (5.4-11.2) 
64 (42-83) 
59 (46-75) 
7.5 (6.1-9.1) 
400 (220-730) 
0.57 (0.35-0.93) 
0.51 (0.42-0.64) 
9.8 (6.7-l 1.5) 
10.7 (9.2-13.4) 
1.7 (1.3-2.3) 
1.6 (1.2-2.1) 
57 (33-100) 
0.69 (0.53-0.89) 
6.7 (4.7-9.4) 
1.4 (0.90-2.2) 
5.4 (4.5-6.5) 
3.0 (1.6-5.7) 
59 (48-73) 
3.5 (1.9-6.6) 
4.8 (3.6-6.4) 
2.7 (1.0-7.0) 
1.9 (0.8-5.0) 
3.2 (2.2-4.6) 
1.0 (0.93-1.1) 
0.39 (0.27-0.57) 
0.56 (0.45-0.70) 
12.2 (9.1-16.3) 
150 (130-180) 
52 (40-68) 
770 (650-920) 
770 (520-l 130) 
92 (68-124) 
1400 (950-2100) 
1.4 (1.1-1.9) 
1.1 (0.69-1.7) 
8.9 (6.9-l 1.6) 
13.2 (9.5-18.3) 
1.8 (1.2-2.6) 
2.1 (1.4-3.2) 
42 (30-57) 
1.1 (0.87-1.4) 
5.1 (2.8-9.0) 
2.4 (1.6-3.7) 
8.1 (7.6-8.5) 
110 (67-180) 
350 (250-490) 
28.7 (20.1-41.0) 
76 (47-123) 
82 (64-106) 
13.3 (9.2-19.4) 
32.9 (28.5-38.1) 
7.7 (6.2-9.5) 
14.1 (13.6-14.7) 
3.6 (3.1-4.1) 
(59-l 17) 
6:: (410-890) 
6.3 (5.5-7.3) 
70 (50-97) 
60 (43-83) 
11.7 (6.1-22.4) 
540 (510-580) 
1.1 (0.80-1.5) 
4.6 (3.2-6.5) 
41 (37-47) 
Binding of 1 nM [3H]PIA was measured at 37°C. Values are geometric means with 95% confidence limits from n = 
4-6 with rat and n = 3 with calf and guinea pig cerebral cortex membranes, respectively 
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Al receptors of rat and calf brain (table 1). The 
only exception is N6-1-methylcyclopentyladenosine 
(6), which is nearly 5-fold more potent at Al recep- 
tors of rat brain than at calf brain receptors. The 
affinities of these compounds for Al receptors in 
guinea pig cerebral cortex membranes are at most 
only slightly lower than those at Al receptors in rat 
and calf brain. 
In the series of N6-aryl (9) and N6-aralkyl (10, 
11) analogs, however, marked species differences 
in affinities for Al receptors are evident. The 
presence of a phenyl moiety in the N6 substituent 
of adenosine analogs results in a 3-5-fold higher 
affinity at the calf brain Al receptor than at the rat 
brain receptor: this increase in affinity is indepen- 
dent of the distance separating the aromatic ring 
from the p-nitrogen (9-11). The affinities of 
these aryl and aralkyl analogs for Al receptors of 
guinea pig brain are even lower. The three 
heteroaralkyl analogs (12-14) are also more potent 
at the calf brain Al receptor than at the rat brain 
receptor. The N6-2-(4-pyridylethyl)adenosine (13) 
is notable in being 6-fold more potent at calf than 
rat brain. The affinities of these heteroaralkyl 
analogs are even lower for Al receptors of guinea 
pig brain, at which receptors 13 is 30-fold less po- 
tent than at calf brain receptors. 
A functionalized congener approach has recent- 
ly been applied to adenosine to yield compounds 
such as 15-17 [7]. These functionalized congeners 
are also N6-aryladenosines. The methylamido 
derivative of N6-(4-carboxymethyl)phenyladeno- 
sine (15) is about 4-fold more potent in calf brain 
than in rat brain. The incorporation of an addi- 
tional aryl ring (16) results in a very potent analog, 
which has, however, the same affinity in rat and 
calf brain. Further extension of the functionalized 
chain results in a compound with a terminal 
-NHCHzCHzNH2 group (ADAC, 17), which is 
about 3-fold more potent in calf than in rat brain. 
These functionalized congeners are less potent in 
guinea pig brain than in rat brain. 
Stereoselectivity for N6-aralkyladenosine with a 
chiral carbon attached to the N#j nitrogen is noted 
at both Al and A2 adenosine receptors [1,2]. In- 
deed, the higher stereoselectivity of R- and S-PIA 
(18,19) at Al receptors has been widely utilized in 
attempts to define adenosine receptor subclasses. 
The R/S ratio for PIA is about 40-fold in rat 
brain, but only 20-fold in calf brain, mainly 
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because of a 4-fold increase in affinity for S-PIA 
(19) in calf brain compared to an only 2-fold in- 
crease for R-PIA (18). The R/S activity ratio for 
PIA is 23 in guinea pig brain, with both isomers 
being less active in guinea pig than in rat brain. 
The presence of another methyl group on the car- 
bon attached to the N6 nitrogen in PIAs removes 
chirality and creates a tertiary carbon attached to 
the N6 nitrogen in MePIA (20). MePIA has the 
same affinity in rat and calf brain, thereby being 
2.5- and 12-fold, respectively, less potent than S- 
PIA (19). It is much less potent in guinea pig brain. 
All of the N6-aryl and N6-aralkyl analogs (9-20) 
have lower affinity in guinea pig than in rat brain. 
All but one (MePIA, 20) have lower affinity for rat 
brain than for calf brain. The most striking ex- 
amples of species differences are for 
N6-phenyladenosine (9), the heteroaralkyl analog 
13 and for the functionalized congener (ADAC, 
17), which are respectively 30- to 36-fold less po- 
tent in guinea pig brain than in calf brain. 
NECA (21) was the most potent carboxamide 
derivative tested. NECA (21) is about 8-14-fold 
more potent than the 5 ‘-N-methylamido analog 
(22) and the unsubstituted 5’ -amide analog (23) in 
rat, calf and guinea pig brain. The carboxamides 
22 and 23 are equivalent to each other in activity 
in the three species. However, the carboxamide 
derivatives (21-23) are 7-13-fold less potent in 
calf brain than in rat and guinea pig brain. This is 
of particular interest, because the different order 
of potency for R-PIA and NECA has been widely 
used for the definition of the subclass of adenosine 
receptor involved in a particular function [ 1,2]. R- 
PIA (18) is 6.5-fold more potent than NECA (21) 
at Al receptors of rat brain, 93-fold in calf brain 
and only 1 .&fold more potent in guinea pig brain. 
Alterations in the C2 position of the purine ring 
lead to potent adenosine analogs. 2-Chloro- 
adenosine (24) is as potent as NECA (21) at Al 
receptors of rat brain. With a Ki of 92 nM, 
2-chloroadenosine is about 1Zfold less potent in 
calf brain than in rat brain. 2-Phenylamino- 
adenosine (25) is of particular interest because it is 
the first adenosine analog found to be significantly 
more potent at A2 receptors than at Al receptors 
[ 131. This analog (25) is equally potent at 
Al-binding sites of rat and guinea pig brain, but 
about 3-fold less potent in calf brain. Therefore, at 
least some adenosine analogs with substitutions at 
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CS of the ribose ring or at C2 of the purine ring 
have reduced affinity to Al-binding sites in calf 
cerebral cortex. 
Recently, a new group of M-substituted NECA 
derivatives has been introduced for receptor 
classification [ 11,141. At the A2 receptor of dog 
coronary artery the potency of the p-modified 
NECA analogs is similar to that of the 
p-substituted adenosines. Thus, an N6 substituent 
exerts the same effect on an adeno- 
sine-5 ’ -uronamide as on an adenosine, but com- 
pletely suppresses the potential of the amide 
function to contribute to vasoactivity [l 11. In con- 
trast, at the adenylate cyclase-coupled A2 recep- 
tors of rat pheochromocytoma (PC12) cells and 
human platelets, the 5 ’ -ethylcarboxamido group 
can modestly increase the potency of certain 
p-substituted adenosines, but in no case is the 
p-substituted NECA more potent than NECA 
[11,14]. At the Al-binding site of rat brain, the 
5 ’ -ethylcarboxamido group (compounds 26-28) 
increases potency about 2-5-fold over that of the 
N6-substituted adenosine. In calf brain the 
N6-substituted NECA derivatives have similar af- 
finity to the N6-substituted adenosines, whereas in 
guinea pig brain an increase in affinity of about 
2-fold occurs for the A@-cyclohexyl- (26) and the 
N6-S-l-phenyl-Zpropyl- (28) NECA derivatives. 
Therefore, the p-substituted NECA derivatives 
appear potentially very useful for receptor 
classification, because the presence of the N6 
substituent enhances or does not change activity at 
Al receptors, while reducing activity of NECA at 
the A2 receptors [11,14]. 
Theophylline (1,3_dimethylxanthine, 29), a well 
known antagonist at adenosine receptors, has 
similar affinity in rat and calf brain (table 2). It is 
somewhat less potent in guinea pig brain. Incor- 
Table 2 
Inhibition of [3H]PIA binding to cerebral cortex membranes by xanthine derivatives 
Xanthine 
Rat 
Inhibition [3H]PIA binding (Ki, nM) 
Calf Guinea pig 
29 Theophylline 12800 (10800-15300) 13500 (7000-26000) 24700 (19800-30800) 
30 8-Phenyltheophylline 76 (58-98) 7.6 (4.0-14.4) 1540 (910-2610) 
31 8-p-Sulfophenyltheophylline 1000 (770-1360) 300 (190-270) 10 100 (7250-13 950) 
32 8-Cyclopentyltheophylline 510 (400-660) 54 (42-69) 1200 (980-1500) 
33 8-Phenylaminotheophylline 5300 (3200-8900) 1200 (500-2900) 21700 (12800-36600) 
34 Caffeine 44000 (31000-63000) 44000 (27000-73000) 47000 (36000-62000) 
35 8-Phenylcaffeine 14700 (12200-17700) 8800 (6300-12600) 25200 (17800-35600) 
36 1,3_Dipropylxanthine 710 (670-750) 340 (230-510) 1310 (1000-1720) 
37 1,3-Dipropyl-8-phenylxanthine 10.0 (5.5-18.2) 0.22 (0.07-0.69) 20.9 (16.3-26.9) 
38 I-(p-Sulfophenyl)-1,3-dipropyl- 
xanthine 140 (110-200) 32 (20-52) 810 (390-1650) 
39 1,3-Dipropyl-8-(p-HzN(CH&- 
NHCOCHZ-OC,&)-xanthine 
(WC) 1.3 (1.0-1.7) 0.15 (0.09-0.24) 16.5 (9.6-28) 
40 1,3-Dipropyl-8-cyclopentylxanthine 1.2 (0.71-1.9) 0.29 (0.21-0.39) 3.9 (2.6-5.9) 
41 1,3-Dipropyl-8-cyclohexylxanthine 1.4 (0.91-2.0) 0.21 (0.1 l-0.43) 4.7 (3.4-6.6) 
42 I-Propargyl-3,7_dimethylxanthine 11000 (9000-13000) 16400 (15 100-17800) 25800 (22400-29700) 
43 1,3-Dimethyl-7-propylxanthine 19800 (15200-25700) 18200 (16200-20500) 33300 (19000-58000) 
44 1,3-Dipropyl-7-methylxanthine 3400 (3500-4400) 2400 (1200-4700) 6200 (4700-8 100) 
45 3-Isobutyl-1-methylxanthine 6200 (5000-7800) 4400 (3700-5200) 8600 (6200-l 1800) 
Binding of 1 nM [3H]PIA was measured at 37’C. Values are geometric means with 95% confidence limits from n = 
3 experiments 
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poration of an S-phenyl group into theophylline 
(30) enhances affinity about 170-fold in rat brain 
and about 1800-fold in calf brain, as reported in 
[lo]. In guinea pig brain, however, the 8-phenyl 
group increases affinity by only about 9-fold. 
8-Phenyltheophylline (30) is thus 1 l-fold more po- 
tent in calf than rat brain and 200-fold more potent 
in calf than guinea pig brain. 8-p- 
Sulfophenyltheophylline (31) is about 3-fold more 
potent in calf than rat brain and about 30-fold 
more potent in calf than guinea pig brain. The 
higher affinity of an 8-substituted xanthine for Al 
receptors in calf brain compared to rat or guinea 
pig brain is also observed with 8-cyclo- 
pentyltheophylline (32). This xanthine is only 
2-fold less potent in guinea pig brain than in rat 
brain. Separation of the phenyl group of 
8-phenyltheophylline by an amine nitrogen so as to 
yield 8-phenylaminotheophylline (33) yields a weak 
antagonist hat shows a 4.5-fold difference in af- 
finity between calf and rat brain, and a 4-fold dif- 
ference between rat and guinea pig brain. 
Caffeine (34) shows the same affinity for Al 
receptor binding sites of rat, calf and guinea pig 
brain, respectively (table 2). In this case, incor- 
poration of an 8-phenyl group increased affinity 
by 5-fold in calf, 3-fold in rat and 2-fold in guinea 
pig brain, respectively. Thus, effects of an 
8-phenyl group are less species dependent for caf- 
feine than for theophylline. Replacement of the 
methyl groups of theophylline with propyl groups 
to yield 1,3_dipropylxanthine (36) results in an in- 
crease in affinity of almost 20-fold in rat and 
guinea pig brain and a 40-fold increase in calf 
brain. This xanthine, like theophylline and caf- 
feine, thus shows only slight species differences for 
interactions with brain Al receptors. Remarkable 
further increases in activity occur with 
1,3_dipropylxanthines having 8-aryl substituents. 
Compound 37 is 60-70-fold more potent than 
1,3_dipropylxanthine (36) in rat and guinea pig 
brain and more than 1500-fold more potent in calf 
brain. As recently shown, combinations of 
1,3-dipropyl and 8-phenyl substituents can lead to 
selectivity for Al receptors compared to A2 recep- 
tors [12,15,16]. 
Since many of the potent and/or selective 
8-phenylxanthines have very low water solubility, 
which limits their usefulness in vivo because of low 
drug availability, polar substituents uch as p-sulfo 
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groups have been introduced into the 8-phenyl ring 
to increase water solubility [ 131. As can be seen 
from compounds 31 and 38, these substituents also 
markedly reduce the potency at brain Al receptors 
from all three species. As with other 8-substituted 
xanthines, the same profile of potency pertains for 
the 8-p-sulfophenylxanthines, namely calf > rat > 
guinea pig. 
XAC (39) is a functionalized congener derived 
from 1,3-dipropyl-8-(4-hydroxyphenyl)xanthine 
[17]. It exhibits very high affinity for Al receptors 
of rat and calf brain. As in the case of the func- 
tionalized congener ADAC (17) in the agonist 
series, the high affinity of XAC appears due to the 
presence of the distal ammonium moiety. The 
enhancing effect of a positively charged moiety on 
Al receptor affinity is also noted in conjugates 
with amino acid moieties [18]. Tritiated XAC 
represents the first truly satisfactory antagonist 
radioligand for adenosine receptors [6,17]. It is 
most potent in calf brain, being 9-fold more potent 
in this species than in guinea pig. 
1,3-Dipropyl-8-cyclopentylxanthine (40) and 
1,3-dipropyl-8-cyclohexylxanthine (41) are an- 
tagonists with very high affinity for Al adenosine 
receptors. As with 1,3-dipropyl-8-phenylxanthine 
(37), compounds 40 and 41 have a 3-5-fold higher 
affinity to calf brain Al receptors compared to 
those of rat brain and a 3-4-fold lower affinity in 
guinea pig brain adenosine receptors compared to 
rat brain. 
I-Propargyl-3,7_dimethylxanthine (42) has 
recently been described as a xanthine derivative 
with some selectivity for A2 adenosine receptors 
[ 13,171. The presence of the polar propargyl group 
contributes to a 2-3-fold increase in potency com- 
pared to caffeine in calf and guinea pig brain, 
while having no effect in rat brain. 
1,3-Dimethyl-7-propylxanthine (43) is another 
A2-selective antagonist [13,16]. It is about 2-fold 
more potent than caffeine at Al receptors of calf 
and rat brain, while being only slightly more po- 
tent than caffeine at Al receptors of guinea pig 
brain. 1,3-Dipropyl-7-methylxanthine (44) and 
3-isobutyl-1-methylxanthine (45) are relatively po- 
tent in all three species. These xanthines along with 
theophylline (29), caffeine (34), 1,3-dipropyl- 
xanthine (36) and the other two xanthines (42,43) 
that lack an 8-substituent have nearly equivalent 
activity at Al receptors of rat, calf and guinea pig 
brain. 
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4. DISCUSSION 
The present results provide strong evidence for 
well-defined species differences in the recognition 
site on brain Al receptors for both agonists and 
antagonists. The differences are strongly depen- 
dent on specific molecular features as follows: 
4.1. Agonists 
(i) The presence of a phenyl or heteroaryl moiety 
in the N6 substituent of adenosine analogs greatly 
enhances affinity at the calf brain Al receptor 
resulting in agonists that can be as much as 30-fold 
more potent in calf than in guinea pig brain. 
Potency is intermediate in rat brain. Thus, a 
change or alteration in the structure of the Al 
receptor apparently has occurred in calf brain that 
enhances interactions with an aryl or heteroaryl 
ring. (ii) The presence of a 5 ‘-ethylcarboxamido 
moiety results in a great reduction in potency at Al 
receptors of calf brain compared to rat and guinea 
pig brain. This lowering of affinity in calf brain by 
the 5 ’ -carboxamido moiety is overcome by the 
presence of an N6 substituent. (iii) The presence of 
a 2-substituent results in a slight (compound 25) to 
large (compound 18) reduction in potency at the 
Al receptor of calf brain compared to rat and 
guinea pig brain. 
4.2. Antagonists 
(i) The presence of an 8substituent (either aryl 
or cycloalkyl) greatly enhances affinity at the calf 
brain Al receptor resulting in antagonists that can 
be as much as 200-fold more potent in calf than in 
guinea pig brain. Potency is intermediate in rat 
brain. Xanthines, such as theophylline, caffeine, 
1,3_dipropylxanthine, compounds 42-44 and 
IBMX are equipotent or nearly so in the three 
species. It is tempting to speculate that the altera- 
tion in the Al receptor that affects potency for 
N6-aryl, Nd-aralkyl, or N6-heteroaralkyl sub- 
stituted adenosines is the same alteration that af- 
fects potency of 8-aryl- or 8cycloalkylxanthines: 
i.e. binding of the N6 substituent of an adenosine 
occurs in a similar manner or at the same loci as 
binding of the 8substituent of a xanthine. 
Regardless of the nature of the alterations in the 
brain Al receptor from different species, the 
results provide a caution against extrapolating pro- 
files of potencies for agonist and antagonist from 
one species to another. Whether the species dif- 
ferences in brain Al receptors also occur with Al 
receptors of fat or heart cells, and whether ecogni- 
tion sites for A2 receptors are conserved in dif- 
ferent species remain to be investigated. 
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